Global Toripalimab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Toripalimab market size was valued at US$ 329 million in 2025 and is forecast to a readjusted size of US$ 896 million by 2032 with a CAGR of 13.4% during review period.
Toripalimab is a humanized IgG4 monoclonal antibody and a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor. It works by binding to the PD-1 receptor on T cells, thereby blocking its interaction with PD-L1 and PD-L2. This mechanism relieves tumor-induced immunosuppression and restores and enhances the body’s anti-tumor immune response. Toripalimab is primarily used in the immunotherapy of various malignancies, such as melanoma, non-small cell lung cancer (NSCLC), and nasopharyngeal carcinoma. It has significant clinical value in the field of cancer immunotherapy.In 2025, global production of toripalimab reached approximately 1.2 million vials.
Toripalimab, as one of the first domestically developed and successfully internationalized PD-1 immune checkpoint inhibitors in China, holds an important position in the cancer immunotherapy market. With the continuous rise in global cancer incidence and the expanding clinical application of immunotherapy across multiple solid tumors, the PD-1 inhibitor market is maintaining rapid growth. Toripalimab has achieved relatively high market penetration in China, supported by a broad range of approved indications, the advancement of reimbursement coverage, and strong clinical performance in tumor types such as nasopharyngeal carcinoma. It is also gradually expanding into overseas markets, including Europe and the United States. From a competitive landscape perspective, the market is dominated by global blockbuster products such as pembrolizumab and nivolumab. However, domestic products demonstrate certain competitive advantages driven by pricing benefits and policy support. Looking ahead, with the approval of additional indications and the expansion of international commercialization, the market size of toripalimab is expected to continue growing, strengthening its position in the global PD-1 inhibitor landscape.
This report is a detailed and comprehensive analysis for global Toripalimab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Toripalimab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Toripalimab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Toripalimab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Toripalimab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Toripalimab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Toripalimab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Toripalimab, with price, sales quantity, revenue, and global market share of Toripalimab from 2021 to 2026.
Chapter 3, the Toripalimab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Toripalimab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Toripalimab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Toripalimab.
Chapter 14 and 15, to describe Toripalimab sales channel, distributors, customers, research findings and conclusion.
Toripalimab is a humanized IgG4 monoclonal antibody and a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor. It works by binding to the PD-1 receptor on T cells, thereby blocking its interaction with PD-L1 and PD-L2. This mechanism relieves tumor-induced immunosuppression and restores and enhances the body’s anti-tumor immune response. Toripalimab is primarily used in the immunotherapy of various malignancies, such as melanoma, non-small cell lung cancer (NSCLC), and nasopharyngeal carcinoma. It has significant clinical value in the field of cancer immunotherapy.In 2025, global production of toripalimab reached approximately 1.2 million vials.
Toripalimab, as one of the first domestically developed and successfully internationalized PD-1 immune checkpoint inhibitors in China, holds an important position in the cancer immunotherapy market. With the continuous rise in global cancer incidence and the expanding clinical application of immunotherapy across multiple solid tumors, the PD-1 inhibitor market is maintaining rapid growth. Toripalimab has achieved relatively high market penetration in China, supported by a broad range of approved indications, the advancement of reimbursement coverage, and strong clinical performance in tumor types such as nasopharyngeal carcinoma. It is also gradually expanding into overseas markets, including Europe and the United States. From a competitive landscape perspective, the market is dominated by global blockbuster products such as pembrolizumab and nivolumab. However, domestic products demonstrate certain competitive advantages driven by pricing benefits and policy support. Looking ahead, with the approval of additional indications and the expansion of international commercialization, the market size of toripalimab is expected to continue growing, strengthening its position in the global PD-1 inhibitor landscape.
This report is a detailed and comprehensive analysis for global Toripalimab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Toripalimab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Toripalimab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Toripalimab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Toripalimab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Toripalimab
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Toripalimab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Monoclonal Antibody, mAb
- Bispecific Antibody, BsAb
- 80 mg / 4 mL
- 240 mg / 6 mL
- Innovator
- Generic
- Injection
- Sterile Powder for Injection
- Melanoma
- Non-Small Cell Lung Cancer
- Nasopharyngeal Carcinoma, NPC
- Esophageal Cancer
- Hepatocellular Carcinoma, HCC
- Urothelial Carcinoma
- Others
- Shanghai Junshi Biosciences
- Coherus BioSciences
- Apotex
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Toripalimab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Toripalimab, with price, sales quantity, revenue, and global market share of Toripalimab from 2021 to 2026.
Chapter 3, the Toripalimab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Toripalimab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Toripalimab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Toripalimab.
Chapter 14 and 15, to describe Toripalimab sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Toripalimab Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Monoclonal Antibody, mAb
1.3.3 Bispecific Antibody, BsAb
1.4 Market Analysis by Specification
1.4.1 Overview: Global Toripalimab Consumption Value by Specification: 2021 Versus 2025 Versus 2032
1.4.2 80 mg / 4 mL
1.4.3 240 mg / 6 mL
1.5 Market Analysis by Sales Channels
1.5.1 Overview: Global Toripalimab Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
1.5.2 Innovator
1.5.3 Generic
1.6 Market Analysis by Dosage Form
1.6.1 Overview: Global Toripalimab Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
1.6.2 Injection
1.6.3 Sterile Powder for Injection
1.7 Market Analysis by Application
1.7.1 Overview: Global Toripalimab Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.7.2 Melanoma
1.7.3 Non-Small Cell Lung Cancer
1.7.4 Nasopharyngeal Carcinoma, NPC
1.7.5 Esophageal Cancer
1.7.6 Hepatocellular Carcinoma, HCC
1.7.7 Urothelial Carcinoma
1.7.8 Others
1.8 Global Toripalimab Market Size & Forecast
1.8.1 Global Toripalimab Consumption Value (2021 & 2025 & 2032)
1.8.2 Global Toripalimab Sales Quantity (2021-2032)
1.8.3 Global Toripalimab Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Shanghai Junshi Biosciences
2.1.1 Shanghai Junshi Biosciences Details
2.1.2 Shanghai Junshi Biosciences Major Business
2.1.3 Shanghai Junshi Biosciences Toripalimab Product and Services
2.1.4 Shanghai Junshi Biosciences Toripalimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Shanghai Junshi Biosciences Recent Developments/Updates
2.2 Coherus BioSciences
2.2.1 Coherus BioSciences Details
2.2.2 Coherus BioSciences Major Business
2.2.3 Coherus BioSciences Toripalimab Product and Services
2.2.4 Coherus BioSciences Toripalimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Coherus BioSciences Recent Developments/Updates
2.3 Apotex
2.3.1 Apotex Details
2.3.2 Apotex Major Business
2.3.3 Apotex Toripalimab Product and Services
2.3.4 Apotex Toripalimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Apotex Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: TORIPALIMAB BY MANUFACTURER
3.1 Global Toripalimab Sales Quantity by Manufacturer (2021-2026)
3.2 Global Toripalimab Revenue by Manufacturer (2021-2026)
3.3 Global Toripalimab Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Toripalimab by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Toripalimab Manufacturer Market Share in 2025
3.4.3 Top 6 Toripalimab Manufacturer Market Share in 2025
3.5 Toripalimab Market: Overall Company Footprint Analysis
3.5.1 Toripalimab Market: Region Footprint
3.5.2 Toripalimab Market: Company Product Type Footprint
3.5.3 Toripalimab Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Toripalimab Market Size by Region
4.1.1 Global Toripalimab Sales Quantity by Region (2021-2032)
4.1.2 Global Toripalimab Consumption Value by Region (2021-2032)
4.1.3 Global Toripalimab Average Price by Region (2021-2032)
4.2 North America Toripalimab Consumption Value (2021-2032)
4.3 Europe Toripalimab Consumption Value (2021-2032)
4.4 Asia-Pacific Toripalimab Consumption Value (2021-2032)
4.5 South America Toripalimab Consumption Value (2021-2032)
4.6 Middle East & Africa Toripalimab Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Toripalimab Sales Quantity by Type (2021-2032)
5.2 Global Toripalimab Consumption Value by Type (2021-2032)
5.3 Global Toripalimab Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Toripalimab Sales Quantity by Application (2021-2032)
6.2 Global Toripalimab Consumption Value by Application (2021-2032)
6.3 Global Toripalimab Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Toripalimab Sales Quantity by Type (2021-2032)
7.2 North America Toripalimab Sales Quantity by Application (2021-2032)
7.3 North America Toripalimab Market Size by Country
7.3.1 North America Toripalimab Sales Quantity by Country (2021-2032)
7.3.2 North America Toripalimab Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Toripalimab Sales Quantity by Type (2021-2032)
8.2 Europe Toripalimab Sales Quantity by Application (2021-2032)
8.3 Europe Toripalimab Market Size by Country
8.3.1 Europe Toripalimab Sales Quantity by Country (2021-2032)
8.3.2 Europe Toripalimab Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Toripalimab Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Toripalimab Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Toripalimab Market Size by Region
9.3.1 Asia-Pacific Toripalimab Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Toripalimab Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Toripalimab Sales Quantity by Type (2021-2032)
10.2 South America Toripalimab Sales Quantity by Application (2021-2032)
10.3 South America Toripalimab Market Size by Country
10.3.1 South America Toripalimab Sales Quantity by Country (2021-2032)
10.3.2 South America Toripalimab Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Toripalimab Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Toripalimab Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Toripalimab Market Size by Country
11.3.1 Middle East & Africa Toripalimab Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Toripalimab Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Toripalimab Market Drivers
12.2 Toripalimab Market Restraints
12.3 Toripalimab Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Toripalimab and Key Manufacturers
13.2 Manufacturing Costs Percentage of Toripalimab
13.3 Toripalimab Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Toripalimab Typical Distributors
14.3 Toripalimab Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Toripalimab Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Monoclonal Antibody, mAb
1.3.3 Bispecific Antibody, BsAb
1.4 Market Analysis by Specification
1.4.1 Overview: Global Toripalimab Consumption Value by Specification: 2021 Versus 2025 Versus 2032
1.4.2 80 mg / 4 mL
1.4.3 240 mg / 6 mL
1.5 Market Analysis by Sales Channels
1.5.1 Overview: Global Toripalimab Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
1.5.2 Innovator
1.5.3 Generic
1.6 Market Analysis by Dosage Form
1.6.1 Overview: Global Toripalimab Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
1.6.2 Injection
1.6.3 Sterile Powder for Injection
1.7 Market Analysis by Application
1.7.1 Overview: Global Toripalimab Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.7.2 Melanoma
1.7.3 Non-Small Cell Lung Cancer
1.7.4 Nasopharyngeal Carcinoma, NPC
1.7.5 Esophageal Cancer
1.7.6 Hepatocellular Carcinoma, HCC
1.7.7 Urothelial Carcinoma
1.7.8 Others
1.8 Global Toripalimab Market Size & Forecast
1.8.1 Global Toripalimab Consumption Value (2021 & 2025 & 2032)
1.8.2 Global Toripalimab Sales Quantity (2021-2032)
1.8.3 Global Toripalimab Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Shanghai Junshi Biosciences
2.1.1 Shanghai Junshi Biosciences Details
2.1.2 Shanghai Junshi Biosciences Major Business
2.1.3 Shanghai Junshi Biosciences Toripalimab Product and Services
2.1.4 Shanghai Junshi Biosciences Toripalimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Shanghai Junshi Biosciences Recent Developments/Updates
2.2 Coherus BioSciences
2.2.1 Coherus BioSciences Details
2.2.2 Coherus BioSciences Major Business
2.2.3 Coherus BioSciences Toripalimab Product and Services
2.2.4 Coherus BioSciences Toripalimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Coherus BioSciences Recent Developments/Updates
2.3 Apotex
2.3.1 Apotex Details
2.3.2 Apotex Major Business
2.3.3 Apotex Toripalimab Product and Services
2.3.4 Apotex Toripalimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Apotex Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: TORIPALIMAB BY MANUFACTURER
3.1 Global Toripalimab Sales Quantity by Manufacturer (2021-2026)
3.2 Global Toripalimab Revenue by Manufacturer (2021-2026)
3.3 Global Toripalimab Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Toripalimab by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Toripalimab Manufacturer Market Share in 2025
3.4.3 Top 6 Toripalimab Manufacturer Market Share in 2025
3.5 Toripalimab Market: Overall Company Footprint Analysis
3.5.1 Toripalimab Market: Region Footprint
3.5.2 Toripalimab Market: Company Product Type Footprint
3.5.3 Toripalimab Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Toripalimab Market Size by Region
4.1.1 Global Toripalimab Sales Quantity by Region (2021-2032)
4.1.2 Global Toripalimab Consumption Value by Region (2021-2032)
4.1.3 Global Toripalimab Average Price by Region (2021-2032)
4.2 North America Toripalimab Consumption Value (2021-2032)
4.3 Europe Toripalimab Consumption Value (2021-2032)
4.4 Asia-Pacific Toripalimab Consumption Value (2021-2032)
4.5 South America Toripalimab Consumption Value (2021-2032)
4.6 Middle East & Africa Toripalimab Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Toripalimab Sales Quantity by Type (2021-2032)
5.2 Global Toripalimab Consumption Value by Type (2021-2032)
5.3 Global Toripalimab Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Toripalimab Sales Quantity by Application (2021-2032)
6.2 Global Toripalimab Consumption Value by Application (2021-2032)
6.3 Global Toripalimab Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Toripalimab Sales Quantity by Type (2021-2032)
7.2 North America Toripalimab Sales Quantity by Application (2021-2032)
7.3 North America Toripalimab Market Size by Country
7.3.1 North America Toripalimab Sales Quantity by Country (2021-2032)
7.3.2 North America Toripalimab Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Toripalimab Sales Quantity by Type (2021-2032)
8.2 Europe Toripalimab Sales Quantity by Application (2021-2032)
8.3 Europe Toripalimab Market Size by Country
8.3.1 Europe Toripalimab Sales Quantity by Country (2021-2032)
8.3.2 Europe Toripalimab Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Toripalimab Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Toripalimab Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Toripalimab Market Size by Region
9.3.1 Asia-Pacific Toripalimab Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Toripalimab Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Toripalimab Sales Quantity by Type (2021-2032)
10.2 South America Toripalimab Sales Quantity by Application (2021-2032)
10.3 South America Toripalimab Market Size by Country
10.3.1 South America Toripalimab Sales Quantity by Country (2021-2032)
10.3.2 South America Toripalimab Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Toripalimab Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Toripalimab Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Toripalimab Market Size by Country
11.3.1 Middle East & Africa Toripalimab Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Toripalimab Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Toripalimab Market Drivers
12.2 Toripalimab Market Restraints
12.3 Toripalimab Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Toripalimab and Key Manufacturers
13.2 Manufacturing Costs Percentage of Toripalimab
13.3 Toripalimab Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Toripalimab Typical Distributors
14.3 Toripalimab Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Toripalimab Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Toripalimab Consumption Value by Specification, (USD Million), 2021 & 2025 & 2032
Table 3. Global Toripalimab Consumption Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Table 4. Global Toripalimab Consumption Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 5. Global Toripalimab Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 6. Shanghai Junshi Biosciences Basic Information, Manufacturing Base and Competitors
Table 7. Shanghai Junshi Biosciences Major Business
Table 8. Shanghai Junshi Biosciences Toripalimab Product and Services
Table 9. Shanghai Junshi Biosciences Toripalimab Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 10. Shanghai Junshi Biosciences Recent Developments/Updates
Table 11. Coherus BioSciences Basic Information, Manufacturing Base and Competitors
Table 12. Coherus BioSciences Major Business
Table 13. Coherus BioSciences Toripalimab Product and Services
Table 14. Coherus BioSciences Toripalimab Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 15. Coherus BioSciences Recent Developments/Updates
Table 16. Apotex Basic Information, Manufacturing Base and Competitors
Table 17. Apotex Major Business
Table 18. Apotex Toripalimab Product and Services
Table 19. Apotex Toripalimab Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 20. Apotex Recent Developments/Updates
Table 21. Global Toripalimab Sales Quantity by Manufacturer (2021-2026) & (Units)
Table 22. Global Toripalimab Revenue by Manufacturer (2021-2026) & (USD Million)
Table 23. Global Toripalimab Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 24. Market Position of Manufacturers in Toripalimab, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 25. Head Office and Toripalimab Production Site of Key Manufacturer
Table 26. Toripalimab Market: Company Product Type Footprint
Table 27. Toripalimab Market: Company Product Application Footprint
Table 28. Toripalimab New Market Entrants and Barriers to Market Entry
Table 29. Toripalimab Mergers, Acquisition, Agreements, and Collaborations
Table 30. Global Toripalimab Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 31. Global Toripalimab Sales Quantity by Region (2021-2026) & (Units)
Table 32. Global Toripalimab Sales Quantity by Region (2027-2032) & (Units)
Table 33. Global Toripalimab Consumption Value by Region (2021-2026) & (USD Million)
Table 34. Global Toripalimab Consumption Value by Region (2027-2032) & (USD Million)
Table 35. Global Toripalimab Average Price by Region (2021-2026) & (US$/Unit)
Table 36. Global Toripalimab Average Price by Region (2027-2032) & (US$/Unit)
Table 37. Global Toripalimab Sales Quantity by Type (2021-2026) & (Units)
Table 38. Global Toripalimab Sales Quantity by Type (2027-2032) & (Units)
Table 39. Global Toripalimab Consumption Value by Type (2021-2026) & (USD Million)
Table 40. Global Toripalimab Consumption Value by Type (2027-2032) & (USD Million)
Table 41. Global Toripalimab Average Price by Type (2021-2026) & (US$/Unit)
Table 42. Global Toripalimab Average Price by Type (2027-2032) & (US$/Unit)
Table 43. Global Toripalimab Sales Quantity by Application (2021-2026) & (Units)
Table 44. Global Toripalimab Sales Quantity by Application (2027-2032) & (Units)
Table 45. Global Toripalimab Consumption Value by Application (2021-2026) & (USD Million)
Table 46. Global Toripalimab Consumption Value by Application (2027-2032) & (USD Million)
Table 47. Global Toripalimab Average Price by Application (2021-2026) & (US$/Unit)
Table 48. Global Toripalimab Average Price by Application (2027-2032) & (US$/Unit)
Table 49. North America Toripalimab Sales Quantity by Type (2021-2026) & (Units)
Table 50. North America Toripalimab Sales Quantity by Type (2027-2032) & (Units)
Table 51. North America Toripalimab Sales Quantity by Application (2021-2026) & (Units)
Table 52. North America Toripalimab Sales Quantity by Application (2027-2032) & (Units)
Table 53. North America Toripalimab Sales Quantity by Country (2021-2026) & (Units)
Table 54. North America Toripalimab Sales Quantity by Country (2027-2032) & (Units)
Table 55. North America Toripalimab Consumption Value by Country (2021-2026) & (USD Million)
Table 56. North America Toripalimab Consumption Value by Country (2027-2032) & (USD Million)
Table 57. Europe Toripalimab Sales Quantity by Type (2021-2026) & (Units)
Table 58. Europe Toripalimab Sales Quantity by Type (2027-2032) & (Units)
Table 59. Europe Toripalimab Sales Quantity by Application (2021-2026) & (Units)
Table 60. Europe Toripalimab Sales Quantity by Application (2027-2032) & (Units)
Table 61. Europe Toripalimab Sales Quantity by Country (2021-2026) & (Units)
Table 62. Europe Toripalimab Sales Quantity by Country (2027-2032) & (Units)
Table 63. Europe Toripalimab Consumption Value by Country (2021-2026) & (USD Million)
Table 64. Europe Toripalimab Consumption Value by Country (2027-2032) & (USD Million)
Table 65. Asia-Pacific Toripalimab Sales Quantity by Type (2021-2026) & (Units)
Table 66. Asia-Pacific Toripalimab Sales Quantity by Type (2027-2032) & (Units)
Table 67. Asia-Pacific Toripalimab Sales Quantity by Application (2021-2026) & (Units)
Table 68. Asia-Pacific Toripalimab Sales Quantity by Application (2027-2032) & (Units)
Table 69. Asia-Pacific Toripalimab Sales Quantity by Region (2021-2026) & (Units)
Table 70. Asia-Pacific Toripalimab Sales Quantity by Region (2027-2032) & (Units)
Table 71. Asia-Pacific Toripalimab Consumption Value by Region (2021-2026) & (USD Million)
Table 72. Asia-Pacific Toripalimab Consumption Value by Region (2027-2032) & (USD Million)
Table 73. South America Toripalimab Sales Quantity by Type (2021-2026) & (Units)
Table 74. South America Toripalimab Sales Quantity by Type (2027-2032) & (Units)
Table 75. South America Toripalimab Sales Quantity by Application (2021-2026) & (Units)
Table 76. South America Toripalimab Sales Quantity by Application (2027-2032) & (Units)
Table 77. South America Toripalimab Sales Quantity by Country (2021-2026) & (Units)
Table 78. South America Toripalimab Sales Quantity by Country (2027-2032) & (Units)
Table 79. South America Toripalimab Consumption Value by Country (2021-2026) & (USD Million)
Table 80. South America Toripalimab Consumption Value by Country (2027-2032) & (USD Million)
Table 81. Middle East & Africa Toripalimab Sales Quantity by Type (2021-2026) & (Units)
Table 82. Middle East & Africa Toripalimab Sales Quantity by Type (2027-2032) & (Units)
Table 83. Middle East & Africa Toripalimab Sales Quantity by Application (2021-2026) & (Units)
Table 84. Middle East & Africa Toripalimab Sales Quantity by Application (2027-2032) & (Units)
Table 85. Middle East & Africa Toripalimab Sales Quantity by Country (2021-2026) & (Units)
Table 86. Middle East & Africa Toripalimab Sales Quantity by Country (2027-2032) & (Units)
Table 87. Middle East & Africa Toripalimab Consumption Value by Country (2021-2026) & (USD Million)
Table 88. Middle East & Africa Toripalimab Consumption Value by Country (2027-2032) & (USD Million)
Table 89. Toripalimab Raw Material
Table 90. Key Manufacturers of Toripalimab Raw Materials
Table 91. Toripalimab Typical Distributors
Table 92. Toripalimab Typical Customers
Table 1. Global Toripalimab Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Toripalimab Consumption Value by Specification, (USD Million), 2021 & 2025 & 2032
Table 3. Global Toripalimab Consumption Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Table 4. Global Toripalimab Consumption Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 5. Global Toripalimab Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 6. Shanghai Junshi Biosciences Basic Information, Manufacturing Base and Competitors
Table 7. Shanghai Junshi Biosciences Major Business
Table 8. Shanghai Junshi Biosciences Toripalimab Product and Services
Table 9. Shanghai Junshi Biosciences Toripalimab Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 10. Shanghai Junshi Biosciences Recent Developments/Updates
Table 11. Coherus BioSciences Basic Information, Manufacturing Base and Competitors
Table 12. Coherus BioSciences Major Business
Table 13. Coherus BioSciences Toripalimab Product and Services
Table 14. Coherus BioSciences Toripalimab Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 15. Coherus BioSciences Recent Developments/Updates
Table 16. Apotex Basic Information, Manufacturing Base and Competitors
Table 17. Apotex Major Business
Table 18. Apotex Toripalimab Product and Services
Table 19. Apotex Toripalimab Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 20. Apotex Recent Developments/Updates
Table 21. Global Toripalimab Sales Quantity by Manufacturer (2021-2026) & (Units)
Table 22. Global Toripalimab Revenue by Manufacturer (2021-2026) & (USD Million)
Table 23. Global Toripalimab Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 24. Market Position of Manufacturers in Toripalimab, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 25. Head Office and Toripalimab Production Site of Key Manufacturer
Table 26. Toripalimab Market: Company Product Type Footprint
Table 27. Toripalimab Market: Company Product Application Footprint
Table 28. Toripalimab New Market Entrants and Barriers to Market Entry
Table 29. Toripalimab Mergers, Acquisition, Agreements, and Collaborations
Table 30. Global Toripalimab Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 31. Global Toripalimab Sales Quantity by Region (2021-2026) & (Units)
Table 32. Global Toripalimab Sales Quantity by Region (2027-2032) & (Units)
Table 33. Global Toripalimab Consumption Value by Region (2021-2026) & (USD Million)
Table 34. Global Toripalimab Consumption Value by Region (2027-2032) & (USD Million)
Table 35. Global Toripalimab Average Price by Region (2021-2026) & (US$/Unit)
Table 36. Global Toripalimab Average Price by Region (2027-2032) & (US$/Unit)
Table 37. Global Toripalimab Sales Quantity by Type (2021-2026) & (Units)
Table 38. Global Toripalimab Sales Quantity by Type (2027-2032) & (Units)
Table 39. Global Toripalimab Consumption Value by Type (2021-2026) & (USD Million)
Table 40. Global Toripalimab Consumption Value by Type (2027-2032) & (USD Million)
Table 41. Global Toripalimab Average Price by Type (2021-2026) & (US$/Unit)
Table 42. Global Toripalimab Average Price by Type (2027-2032) & (US$/Unit)
Table 43. Global Toripalimab Sales Quantity by Application (2021-2026) & (Units)
Table 44. Global Toripalimab Sales Quantity by Application (2027-2032) & (Units)
Table 45. Global Toripalimab Consumption Value by Application (2021-2026) & (USD Million)
Table 46. Global Toripalimab Consumption Value by Application (2027-2032) & (USD Million)
Table 47. Global Toripalimab Average Price by Application (2021-2026) & (US$/Unit)
Table 48. Global Toripalimab Average Price by Application (2027-2032) & (US$/Unit)
Table 49. North America Toripalimab Sales Quantity by Type (2021-2026) & (Units)
Table 50. North America Toripalimab Sales Quantity by Type (2027-2032) & (Units)
Table 51. North America Toripalimab Sales Quantity by Application (2021-2026) & (Units)
Table 52. North America Toripalimab Sales Quantity by Application (2027-2032) & (Units)
Table 53. North America Toripalimab Sales Quantity by Country (2021-2026) & (Units)
Table 54. North America Toripalimab Sales Quantity by Country (2027-2032) & (Units)
Table 55. North America Toripalimab Consumption Value by Country (2021-2026) & (USD Million)
Table 56. North America Toripalimab Consumption Value by Country (2027-2032) & (USD Million)
Table 57. Europe Toripalimab Sales Quantity by Type (2021-2026) & (Units)
Table 58. Europe Toripalimab Sales Quantity by Type (2027-2032) & (Units)
Table 59. Europe Toripalimab Sales Quantity by Application (2021-2026) & (Units)
Table 60. Europe Toripalimab Sales Quantity by Application (2027-2032) & (Units)
Table 61. Europe Toripalimab Sales Quantity by Country (2021-2026) & (Units)
Table 62. Europe Toripalimab Sales Quantity by Country (2027-2032) & (Units)
Table 63. Europe Toripalimab Consumption Value by Country (2021-2026) & (USD Million)
Table 64. Europe Toripalimab Consumption Value by Country (2027-2032) & (USD Million)
Table 65. Asia-Pacific Toripalimab Sales Quantity by Type (2021-2026) & (Units)
Table 66. Asia-Pacific Toripalimab Sales Quantity by Type (2027-2032) & (Units)
Table 67. Asia-Pacific Toripalimab Sales Quantity by Application (2021-2026) & (Units)
Table 68. Asia-Pacific Toripalimab Sales Quantity by Application (2027-2032) & (Units)
Table 69. Asia-Pacific Toripalimab Sales Quantity by Region (2021-2026) & (Units)
Table 70. Asia-Pacific Toripalimab Sales Quantity by Region (2027-2032) & (Units)
Table 71. Asia-Pacific Toripalimab Consumption Value by Region (2021-2026) & (USD Million)
Table 72. Asia-Pacific Toripalimab Consumption Value by Region (2027-2032) & (USD Million)
Table 73. South America Toripalimab Sales Quantity by Type (2021-2026) & (Units)
Table 74. South America Toripalimab Sales Quantity by Type (2027-2032) & (Units)
Table 75. South America Toripalimab Sales Quantity by Application (2021-2026) & (Units)
Table 76. South America Toripalimab Sales Quantity by Application (2027-2032) & (Units)
Table 77. South America Toripalimab Sales Quantity by Country (2021-2026) & (Units)
Table 78. South America Toripalimab Sales Quantity by Country (2027-2032) & (Units)
Table 79. South America Toripalimab Consumption Value by Country (2021-2026) & (USD Million)
Table 80. South America Toripalimab Consumption Value by Country (2027-2032) & (USD Million)
Table 81. Middle East & Africa Toripalimab Sales Quantity by Type (2021-2026) & (Units)
Table 82. Middle East & Africa Toripalimab Sales Quantity by Type (2027-2032) & (Units)
Table 83. Middle East & Africa Toripalimab Sales Quantity by Application (2021-2026) & (Units)
Table 84. Middle East & Africa Toripalimab Sales Quantity by Application (2027-2032) & (Units)
Table 85. Middle East & Africa Toripalimab Sales Quantity by Country (2021-2026) & (Units)
Table 86. Middle East & Africa Toripalimab Sales Quantity by Country (2027-2032) & (Units)
Table 87. Middle East & Africa Toripalimab Consumption Value by Country (2021-2026) & (USD Million)
Table 88. Middle East & Africa Toripalimab Consumption Value by Country (2027-2032) & (USD Million)
Table 89. Toripalimab Raw Material
Table 90. Key Manufacturers of Toripalimab Raw Materials
Table 91. Toripalimab Typical Distributors
Table 92. Toripalimab Typical Customers
LIST OF FIGURES
Figure 1. Toripalimab Picture
Figure 2. Global Toripalimab Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Toripalimab Revenue Market Share by Type in 2025
Figure 4. Monoclonal Antibody, mAb Examples
Figure 5. Bispecific Antibody, BsAb Examples
Figure 6. Global Toripalimab Revenue by Specification, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Toripalimab Revenue Market Share by Specification in 2025
Figure 8. 80 mg / 4 mL Examples
Figure 9. 240 mg / 6 mL Examples
Figure 10. Global Toripalimab Revenue by Sales Channels, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Toripalimab Revenue Market Share by Sales Channels in 2025
Figure 12. Innovator Examples
Figure 13. Generic Examples
Figure 14. Global Toripalimab Revenue by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 15. Global Toripalimab Revenue Market Share by Dosage Form in 2025
Figure 16. Injection Examples
Figure 17. Sterile Powder for Injection Examples
Figure 18. Global Toripalimab Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 19. Global Toripalimab Revenue Market Share by Application in 2025
Figure 20. Melanoma Examples
Figure 21. Non-Small Cell Lung Cancer Examples
Figure 22. Nasopharyngeal Carcinoma, NPC Examples
Figure 23. Esophageal Cancer Examples
Figure 24. Hepatocellular Carcinoma, HCC Examples
Figure 25. Urothelial Carcinoma Examples
Figure 26. Others Examples
Figure 27. Global Toripalimab Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 28. Global Toripalimab Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 29. Global Toripalimab Sales Quantity (2021-2032) & (Units)
Figure 30. Global Toripalimab Price (2021-2032) & (US$/Unit)
Figure 31. Global Toripalimab Sales Quantity Market Share by Manufacturer in 2025
Figure 32. Global Toripalimab Revenue Market Share by Manufacturer in 2025
Figure 33. Producer Shipments of Toripalimab by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 34. Top 3 Toripalimab Manufacturer (Revenue) Market Share in 2025
Figure 35. Top 6 Toripalimab Manufacturer (Revenue) Market Share in 2025
Figure 36. Global Toripalimab Sales Quantity Market Share by Region (2021-2032)
Figure 37. Global Toripalimab Consumption Value Market Share by Region (2021-2032)
Figure 38. North America Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 39. Europe Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 40. Asia-Pacific Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 41. South America Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 42. Middle East & Africa Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 43. Global Toripalimab Sales Quantity Market Share by Type (2021-2032)
Figure 44. Global Toripalimab Consumption Value Market Share by Type (2021-2032)
Figure 45. Global Toripalimab Average Price by Type (2021-2032) & (US$/Unit)
Figure 46. Global Toripalimab Sales Quantity Market Share by Application (2021-2032)
Figure 47. Global Toripalimab Revenue Market Share by Application (2021-2032)
Figure 48. Global Toripalimab Average Price by Application (2021-2032) & (US$/Unit)
Figure 49. North America Toripalimab Sales Quantity Market Share by Type (2021-2032)
Figure 50. North America Toripalimab Sales Quantity Market Share by Application (2021-2032)
Figure 51. North America Toripalimab Sales Quantity Market Share by Country (2021-2032)
Figure 52. North America Toripalimab Consumption Value Market Share by Country (2021-2032)
Figure 53. United States Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 54. Canada Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 55. Mexico Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 56. Europe Toripalimab Sales Quantity Market Share by Type (2021-2032)
Figure 57. Europe Toripalimab Sales Quantity Market Share by Application (2021-2032)
Figure 58. Europe Toripalimab Sales Quantity Market Share by Country (2021-2032)
Figure 59. Europe Toripalimab Consumption Value Market Share by Country (2021-2032)
Figure 60. Germany Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 61. France Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 62. United Kingdom Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 63. Russia Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 64. Italy Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 65. Asia-Pacific Toripalimab Sales Quantity Market Share by Type (2021-2032)
Figure 66. Asia-Pacific Toripalimab Sales Quantity Market Share by Application (2021-2032)
Figure 67. Asia-Pacific Toripalimab Sales Quantity Market Share by Region (2021-2032)
Figure 68. Asia-Pacific Toripalimab Consumption Value Market Share by Region (2021-2032)
Figure 69. China Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 70. Japan Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 71. South Korea Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 72. India Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 73. Southeast Asia Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 74. Australia Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 75. South America Toripalimab Sales Quantity Market Share by Type (2021-2032)
Figure 76. South America Toripalimab Sales Quantity Market Share by Application (2021-2032)
Figure 77. South America Toripalimab Sales Quantity Market Share by Country (2021-2032)
Figure 78. South America Toripalimab Consumption Value Market Share by Country (2021-2032)
Figure 79. Brazil Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 80. Argentina Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 81. Middle East & Africa Toripalimab Sales Quantity Market Share by Type (2021-2032)
Figure 82. Middle East & Africa Toripalimab Sales Quantity Market Share by Application (2021-2032)
Figure 83. Middle East & Africa Toripalimab Sales Quantity Market Share by Country (2021-2032)
Figure 84. Middle East & Africa Toripalimab Consumption Value Market Share by Country (2021-2032)
Figure 85. Turkey Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 86. Egypt Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 87. Saudi Arabia Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 88. South Africa Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 89. Toripalimab Market Drivers
Figure 90. Toripalimab Market Restraints
Figure 91. Toripalimab Market Trends
Figure 92. Porters Five Forces Analysis
Figure 93. Manufacturing Cost Structure Analysis of Toripalimab in 2025
Figure 94. Manufacturing Process Analysis of Toripalimab
Figure 95. Toripalimab Industrial Chain
Figure 96. Sales Channel: Direct to End-User vs Distributors
Figure 97. Direct Channel Pros & Cons
Figure 98. Indirect Channel Pros & Cons
Figure 99. Methodology
Figure 100. Research Process and Data Source
Figure 1. Toripalimab Picture
Figure 2. Global Toripalimab Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Toripalimab Revenue Market Share by Type in 2025
Figure 4. Monoclonal Antibody, mAb Examples
Figure 5. Bispecific Antibody, BsAb Examples
Figure 6. Global Toripalimab Revenue by Specification, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Toripalimab Revenue Market Share by Specification in 2025
Figure 8. 80 mg / 4 mL Examples
Figure 9. 240 mg / 6 mL Examples
Figure 10. Global Toripalimab Revenue by Sales Channels, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Toripalimab Revenue Market Share by Sales Channels in 2025
Figure 12. Innovator Examples
Figure 13. Generic Examples
Figure 14. Global Toripalimab Revenue by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 15. Global Toripalimab Revenue Market Share by Dosage Form in 2025
Figure 16. Injection Examples
Figure 17. Sterile Powder for Injection Examples
Figure 18. Global Toripalimab Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 19. Global Toripalimab Revenue Market Share by Application in 2025
Figure 20. Melanoma Examples
Figure 21. Non-Small Cell Lung Cancer Examples
Figure 22. Nasopharyngeal Carcinoma, NPC Examples
Figure 23. Esophageal Cancer Examples
Figure 24. Hepatocellular Carcinoma, HCC Examples
Figure 25. Urothelial Carcinoma Examples
Figure 26. Others Examples
Figure 27. Global Toripalimab Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 28. Global Toripalimab Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 29. Global Toripalimab Sales Quantity (2021-2032) & (Units)
Figure 30. Global Toripalimab Price (2021-2032) & (US$/Unit)
Figure 31. Global Toripalimab Sales Quantity Market Share by Manufacturer in 2025
Figure 32. Global Toripalimab Revenue Market Share by Manufacturer in 2025
Figure 33. Producer Shipments of Toripalimab by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 34. Top 3 Toripalimab Manufacturer (Revenue) Market Share in 2025
Figure 35. Top 6 Toripalimab Manufacturer (Revenue) Market Share in 2025
Figure 36. Global Toripalimab Sales Quantity Market Share by Region (2021-2032)
Figure 37. Global Toripalimab Consumption Value Market Share by Region (2021-2032)
Figure 38. North America Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 39. Europe Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 40. Asia-Pacific Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 41. South America Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 42. Middle East & Africa Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 43. Global Toripalimab Sales Quantity Market Share by Type (2021-2032)
Figure 44. Global Toripalimab Consumption Value Market Share by Type (2021-2032)
Figure 45. Global Toripalimab Average Price by Type (2021-2032) & (US$/Unit)
Figure 46. Global Toripalimab Sales Quantity Market Share by Application (2021-2032)
Figure 47. Global Toripalimab Revenue Market Share by Application (2021-2032)
Figure 48. Global Toripalimab Average Price by Application (2021-2032) & (US$/Unit)
Figure 49. North America Toripalimab Sales Quantity Market Share by Type (2021-2032)
Figure 50. North America Toripalimab Sales Quantity Market Share by Application (2021-2032)
Figure 51. North America Toripalimab Sales Quantity Market Share by Country (2021-2032)
Figure 52. North America Toripalimab Consumption Value Market Share by Country (2021-2032)
Figure 53. United States Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 54. Canada Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 55. Mexico Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 56. Europe Toripalimab Sales Quantity Market Share by Type (2021-2032)
Figure 57. Europe Toripalimab Sales Quantity Market Share by Application (2021-2032)
Figure 58. Europe Toripalimab Sales Quantity Market Share by Country (2021-2032)
Figure 59. Europe Toripalimab Consumption Value Market Share by Country (2021-2032)
Figure 60. Germany Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 61. France Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 62. United Kingdom Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 63. Russia Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 64. Italy Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 65. Asia-Pacific Toripalimab Sales Quantity Market Share by Type (2021-2032)
Figure 66. Asia-Pacific Toripalimab Sales Quantity Market Share by Application (2021-2032)
Figure 67. Asia-Pacific Toripalimab Sales Quantity Market Share by Region (2021-2032)
Figure 68. Asia-Pacific Toripalimab Consumption Value Market Share by Region (2021-2032)
Figure 69. China Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 70. Japan Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 71. South Korea Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 72. India Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 73. Southeast Asia Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 74. Australia Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 75. South America Toripalimab Sales Quantity Market Share by Type (2021-2032)
Figure 76. South America Toripalimab Sales Quantity Market Share by Application (2021-2032)
Figure 77. South America Toripalimab Sales Quantity Market Share by Country (2021-2032)
Figure 78. South America Toripalimab Consumption Value Market Share by Country (2021-2032)
Figure 79. Brazil Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 80. Argentina Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 81. Middle East & Africa Toripalimab Sales Quantity Market Share by Type (2021-2032)
Figure 82. Middle East & Africa Toripalimab Sales Quantity Market Share by Application (2021-2032)
Figure 83. Middle East & Africa Toripalimab Sales Quantity Market Share by Country (2021-2032)
Figure 84. Middle East & Africa Toripalimab Consumption Value Market Share by Country (2021-2032)
Figure 85. Turkey Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 86. Egypt Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 87. Saudi Arabia Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 88. South Africa Toripalimab Consumption Value (2021-2032) & (USD Million)
Figure 89. Toripalimab Market Drivers
Figure 90. Toripalimab Market Restraints
Figure 91. Toripalimab Market Trends
Figure 92. Porters Five Forces Analysis
Figure 93. Manufacturing Cost Structure Analysis of Toripalimab in 2025
Figure 94. Manufacturing Process Analysis of Toripalimab
Figure 95. Toripalimab Industrial Chain
Figure 96. Sales Channel: Direct to End-User vs Distributors
Figure 97. Direct Channel Pros & Cons
Figure 98. Indirect Channel Pros & Cons
Figure 99. Methodology
Figure 100. Research Process and Data Source
